Watson Pharmaceuticals (Actavis Inc.) / Specifar Pharmaceuticals S.A.

Generic Pharmaceuticals (European branded-generics)

$6.0B Greek pharma market 2011 (€~6B)

Disease Overview

Branded-generics is the European go-to-market model for off-patent small molecules under company brand names rather than INN — protecting margins versus pure-generic price erosion. Greece had one of Europe's lowest generic-utilization rates in 2011, creating volume upside as governments sought cost containment.

Competitive Landscape

European branded-generics in 2011 was a consolidating segment dominated by Teva (post-Ratiopharm, 2010), Sandoz/Novartis, Mylan (post-Merck KGaA generics, 2007), Stada, Krka, and Actavis (then private). Watson, having entered Europe via the 2009 Arrow Group acquisition, was sub-scale in southern Europe and used Specifar to add a top-five Greek branded-generics platform. The strategic prize was Specifar's generic esomeprazole tablet — a Nexium (AstraZeneca, ~$4.4B WW 2011 sales) reference product — slated for late-2011 EU launch with up to €40M earnout tied to its profitability. Specifar also brought ~400 marketing authorizations across 36 countries and ~1B-dose annual manufacturing capacity expanding to 3-5B doses, letting Watson convert third-party-licensed product back to in-house production. The deal was a clean tuck-in with immediate accretion potential rather than a transformational consolidation play, but it materially deepened Watson's southern-European footprint ahead of its 2012 Actavis combination.